Evaluation of the Archimedes™ System for Transparenchymal Nodule Access

Not Applicable

Terminated

• Conditions: Lung Cancer
• Interventions: Device: Archimedes System

• Registration Number: NCT02460120
• Lead Sponsor: Broncus Medical Inc

Brief Summary

The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs. This study is being conducted to confirm the performance of the Archimedes System in patients who are scheduled for standard bronchoscopy to diagnose highly suspicious lung cancer or metastatic disease. Navigation to and sampling of the patient's lung cancer tumor is conducted.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-05-28
• Study First Submitted QC: 2015-06-01
• Study First Posted: 2015-06-02
• Study Start: 2015-07
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-26
• Last Update Posted: 2017-01-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

1. Age 21-75 years at screening
2. Highly suspicious SPN, defined as distinct nodule with a diameter of ≥8mm in its largest dimension
3. No known endobronchial tumor
4. Tumor located anywhere in parenchymal tissue >1 cm from pleura and accessible bronchoscopically through a POE.
5. Willing to participate in all aspects of study protocol for duration of study
6. Able to understand study requirements
7. Signs study-related informed consent document

Exclusion Criteria

1. Any contraindication to bronchoscopy, for example:

   • Untreatable life-threatening arrhythmias
   • Inability to adequately oxygenate the patient during the procedure
   • Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated)
   • Recent myocardial infarction
   • Previously diagnosed high-grade tracheal obstruction
   • Uncorrectable coagulopathy

2. Known coagulopathy

3. Platelet dysfunction or platelet count < 100 x 103 cells/mm3

4. History of major bleeding with bronchoscopy

5. Suspected pulmonary hypertension: additional testing required, such as echocardiogram

6. Moderate-to-severe pulmonary fibrosis

7. Severe emphysema or COPD: additional testing and PI consent is required

8. Bullae >5 cm located in vicinity of target SPN

9. Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example:

   • ASA class > 3
   • > stage 3 heart failure
   • severe cachexia
   • severe respiratory insufficiency or hypoxia

10. Ongoing systemic infection

11. Contraindication to general anesthesia

12. Inability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel) prior to procedure

13. Participation in any other study in last 30 days

14. Prior thoracic surgery on the same side of the lung as the SPN.

15. Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study.

16. Life expectancy of less than one year.

17. Scheduled for lung surgery within 72hrs post-scheduled diagnostic bronchoscopy

18. Pregnancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Navigation and tissue sampling	Archimedes System	Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System

Primary Outcome Measures

Name	Time	Method
Proportion of biopsies yielding tissue sufficient for diagnosis	Up to 1 year	The the number of nodules with at least one biopsy sufficient for a definitive tissue diagnosis divided by the number of nodules sampled by the Archimedes System.

Secondary Outcome Measures

Name	Time	Method
Procedure planning time	Up to 1 year	The time from selecting the patient CT until the tunnel path has been selected, reviewed and exported.
Nodule access time	Up to 1 year	The time from the start of navigation until the sheath has been placed at the first biopsy target.
Fluoroscopy time	Up to 1 year	The total fluoroscopy time from the start of fused-fluoroscopic navigational guidance to the time the devices are removed from the point of entry.
Patient registration time	Up to 1 year	The total time it takes to correlate the patient's position via fluoroscopy with the navigational guidance system.

Trial Locations

Locations (1)

Cancer Treatment Centers of America at Southwestern Regional Medical Center; 🇺🇸 Tulsa, Oklahoma, United States